Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Bevacizumab; Capecitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Histologically or cytologically documented colorectal adenocarcinoma

• ECOG performance status of 2 or lower

• Adequate bone marrow function

• Adequate kidney function

• Adequate liver function

• Informed consent

Exclusion Criteria:

• Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start

• Known allergy to study drugs